Lankelma J M, Nieuwdorp M, de Vos W M, Wiersinga W J
Department of Internal Medicine, Centre for Infection and Immunity Amsterdam (CINIMA) and Centre for Experimental Molecular Medicine (CEMM), Academic Medical Centre, University of Amsterdam, Amsterdam, the Netherlands.
Neth J Med. 2015 Feb;73(2):61-8.
The human gut microbiota may be viewed as an organ, executing numerous functions in metabolism, development of the immune system and host defence against pathogens. It may therefore be involved in the development of a range of diseases such as gastrointestinal infections, inflammatory bowel disease, allergy and diabetes mellitus. Reversely, certain therapies that are often used, such as antibiotics and chemotherapy, may negatively affect the composition and function of the gut microbiota and thereby the wellbeing of patients. As the microbiota research field is currently moving from association studies to intervention studies and even clinical trials, implementation of this new knowledge into clinical practice is coming near. Several therapeutic interventions that target the gut microbiota are being evaluated, ranging from supplementation of food components to transplantation of faecal microbiota. In this review we provide an overview of current literature on the gut microbiota in both a healthy state and a range of diseases that are relevant for internal medicine. In anticipation of gut microbiota-targeted therapies, it is important to realise the key function of the gut microbiota in physiological processes and the collateral damage that may be caused when disrupting this ecosystem within us.
人类肠道微生物群可被视为一个器官,在新陈代谢、免疫系统发育以及宿主抵御病原体方面执行着众多功能。因此,它可能参与一系列疾病的发生发展,如胃肠道感染、炎症性肠病、过敏和糖尿病。反之,一些常用的治疗方法,如抗生素和化疗,可能会对肠道微生物群的组成和功能产生负面影响,进而影响患者的健康。随着微生物群研究领域目前正从关联研究转向干预研究甚至临床试验,将这一新知识应用于临床实践已指日可待。几种针对肠道微生物群的治疗干预措施正在评估中,从补充食物成分到粪便微生物群移植不等。在这篇综述中,我们概述了当前关于健康状态下以及一系列与内科相关疾病中的肠道微生物群的文献。鉴于针对肠道微生物群的治疗,重要的是要认识到肠道微生物群在生理过程中的关键作用以及破坏我们体内这个生态系统时可能造成的附带损害。